Ovid Therapeutics Inc. 8K

Ovid Therapeutics reported Q2 2026 results, advanced key CNS clinical programs (OV4071 and OV329), executed a monetization transaction for soticlestat with a Perceptive Advisors–backed NewCo and Takeda, strengthened its leadership and board, and confirmed a cash runway into 2029 despite higher operating losses.

On August 13, 2026, Ovid Therapeutics Inc. reported its second quarter 2026 financial results and provided a broad business update, highlighting clinical progress for OV4071, the first oral direct KCC2 activator in an ongoing Phase 1 study with plans for a ketamine challenge study in 2H 2026, and OV329, a next‑generation GABA-AT inhibitor now in Phase 2 trials for treatment‑resistant focal onset seizures and other seizure-related indications, with multiple proof‑of‑concept and photosensitivity studies initiated or planned through 2027. The company also detailed a significant strategic transaction in which a newly formed Perceptive Advisors–backed NewCo acquired global rights to soticlestat from Ovid and Takeda, giving Ovid an equity stake and eligibility for up to $294.5 million in potential milestones and low- to mid-single digit royalties on future net sales, some of which will be shared with Ligand under a prior royalty monetization agreement. Additionally, Ovid strengthened its leadership and governance by appointing Kevin Norrett as Chief Business Officer, promoting Charles Carter to Chief Financial Officer (with former CFO Jeffrey Rona remaining as an advisor through 2027), adding Executive R&D Advisor Eliseo Salinas and Chief Strategy Officer Victoria Fort, and appointing physician‑scientist Anna Greka to its Board of Directors. Financially, Ovid reported cash, cash equivalents and marketable securities of $169.8 million as of June 30, 2026, bolstered by approximately $53.9 million of warrant exercise proceeds in April 2026, and indicated that its cash runway is expected to extend into 2029 despite a net loss of $15.0 million for the quarter driven by increased R&D and G&A expenses associated with its expanded development programs and corporate activities.

Filing Facts

CIK

1636651

Ticker

-

Form

8K

Source Type

sec

Accession

0001628280-26-056497

Alert Tier

6